HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Expert Panel Opposes OTC Ibuprofen/Phenylephrine Combo, Hydrocortisone 1%

Executive Summary

Two prescription-to-OTC switch applications rejected by Germany’s Expert Committee for Prescription: preparations containing a combination of ibuprofen and phenylephrine hydrochloride and hydrocortisone 1% for external use.

You may also be interested in...



Gimme Some Skin: New German Dermatology Products From Engelhard, Medice, Sandoz And Stada

New OTC dermatology products on the German market, including line extensions from Englehard, Medice and Stada and a 0.5% hydrocortisone cream from Sandoz.

‘No Pain, No Gain’ in Germany’s OTC Market: Pain-Relief Launches From GSK and Fysioline, Aspirin Complex Returns

GSK adds medicine-free heat patch to Voltaren range, Fysioline launches Arthro Cream based on its trademarked ‘Ice Power’ menthol combination, and pharmacists restock Bayer's blockbuster drug Aspirin Complex after supply problems.

Germany’s OTC Market in 2018: Online Sees Double-Digit Growth, Bionorica’s Canephron Uno Tops New Launches

Germany's online channel continued to expand to expand in 2018, with OTC product sales via mail-order pharmacy growing almost 10-times faster than through bricks-and-mortar pharmacy. Meanwhile, GSK's Voltaren brand was top-seller through both channels and Bionorica's Canephron Uno was the best-selling launch during the 12 months. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

AG032745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel